Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.62 |
| ▸ | IKBKB | O14920 | 2/20 | 0.59 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.57 |
| ▸ | CDK2 | P24941 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | PLK1 | P53350 | 1/20 | 0.54 |
| ▸ | JAK3 | P52333 | 3/20 | 0.54 |
| ▸ | JAK2 | O60674 | 3/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.52 |
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19603161 | 0.89 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D | |
| SCHEMBL14021043 | 0.88 | PIK3CG (0.62) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D | |
| SCHEMBL13049909 | 0.86 | PIK3CA (0.66) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D | |
| SCHEMBL14469872 | 0.86 | PIK3CG (0.62) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D | |
| SCHEMBL4062045 | 0.85 | CAMK2D (0.78) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D | |
| SCHEMBL4072590 | 0.84 | PIK3CA (0.70) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D | |
| SCHEMBL14021024 | 0.84 | PIK3CA (0.63) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D | |
| SCHEMBL14021250 | 0.84 | CAMK2D (0.56) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D | |
| SCHEMBL4070306 | 0.84 | MAPK8 (0.77) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D | |
| SCHEMBL14021028 | 0.83 | PIK3CA (0.64) | PIK3CAPIK3CBPIK3CGIKBKBCAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327788-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-20170327788-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725694-B2 | Composition for collecting and preserving placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598669-B2 | Composition for collecting placental stem cells and methods of using the composition | ANTHROGENESIS CORPORATION (US) | 2017-03-21 | — | — | US | disclosed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1349841-B1 | ANILINOPYRIMIDINE DERIVATIVES AS IKK INHIBITORS AND COMPOSITIONS AND METHODS RELATED THERETO | SIGNAL PHARM LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008091925-A2 | TREATMENT OF AORTIC DISSECTION OR ANEURYSM | COOK INCORPORATED (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | CELGENE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | Celularity, Inc. | 2007-08-16 | — | — | US | disclosed |
| US-7129242-B2 | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-10-31 | — | — | US | disclosed |
| US-7122544-B2 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC (US) | 2006-10-17 | — | — | US | disclosed |
| US-20060030576-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2006-02-09 | — | — | US | disclosed |
| WO-2004084901-A1 | METHODS FOR TREATING OR PREVENTING AN INFLAMMATORY OR METABOLIC CONDITION BY INHIBITING JNK | SIGNAL PHARMACEUTICALS, LLC (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-06-03 | — | — | US | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | CELGENE CORPORATION | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106634-A1 | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK | MAPK6, MAPKAPK2, DUSP6 | PIK3CA 2501/4885PIK3CB 2338/4885PIK3CG 3039/4885 |
| US-20040087642-A1 | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain | MAP3K1, MAP3K6, MAPKAPK2 | PIK3CA 814/4885PIK3CB 890/4885PIK3CG 906/4885 |
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | PGF, ALPP, CPA1 | PIK3CA 1138/4885PIK3CB 842/4885PIK3CG 893/4885 |
| US-20060030576-A1 | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto | NFKBIA, IKBKB, IKBKE | PIK3CA 26/4885PIK3CB 35/4885PIK3CG 61/4885 |
| US-20070270448-A1 | Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders | MAP3K6, MAP3K1, MAPK1 | PIK3CA 1084/4885PIK3CB 1775/4885PIK3CG 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.